NDAORALCAPSULEPriority Review
Approved
Jul 1980
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VANSIL (oxamniquine) is an oral small-molecule anthelmintic approved in 1980 for treating schistosomiasis, a parasitic infection affecting millions globally. The drug works by disrupting the neuromuscular function of schistosome parasites, leading to their paralysis and elimination.
LOE Approaching
Product is nearing loss of exclusivity with moderate competitive pressure (30), indicating shrinking team resources and transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on VANSIL offers limited growth career trajectory but valuable experience in managing legacy products, global health markets, and LOE strategy. Positions are shrinking as the product approaches loss of exclusivity, making this a transition or consolidation role rather than an expansion opportunity.
Product ManagerMedical Science Liaison
Worked on VANSIL at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.